Malnutrition, PROs and Remote Therapeutic Monitoring in gastrointestinal oncology
Nutritional Risk Assessment and Impact on Patient-Reported Outcomes (PROs) in Gastrointestinal (GI) Oncology: Actionability of Remote Therapeutic Monitoring (RTM) in Predicting Nutritional Decline
October 26, 2026
4 minutes
Authors & Affiliation
C. Neuzillet (Paul Brousse) ; D. Cardenas (Gustave Roussy), M. Valery, G (Gustave Roussy). Camilleri (Gustave Roussy) ; M. Delay (Institut Curie), E. Molina (Institut Curie) ; L. Polastro (Institut Jules Bordet) ; J.P. Metges (CHU Brest) ; J. Martin (Hôpital Européen de Marseille) ; A. Thirot-Bidault (HP d’Anthony) ; H. Abahssain (CH de Valencienne) ; F. Audemar (CH de la Côte Basque), M. Brugel (CH de la Côte Basque) ; J. Desrame (Hôpital Privé Jean Mermoz) ; G. Ulmann (Nutricia), C. David-Basei (Nutricia) ; S. Jetley (Resilience Care), A. Guillou (Resilience Care), A. Yazigi (Resilience Care), C. Ferté (Resilience Care).
Malnutrition is a major challenge for patients with gastrointestinal cancers, with a potential impact on quality of life and treatment tolerability. Presented at ESMO 2026, this study explores how Remote Therapeutic Monitoring (RTM), by combining the MUST score, patient-reported symptoms, and social determinants of health, could help identify at-risk patients earlier and support more proactive nutritional care.
